Proteo Inc./Proteo Biotech AG: European Medicines Agency European Medicines Evaluation Agency Recommends Orphan Drug Status for Elafin in the Treatment of Esophagus Carcinoma

Published: Nov 16, 2009

IRVINE, Calif. & KIEL, Germany--(BUSINESS WIRE)--Proteo, Inc. (OTCBB: PTEO; Frankfurter Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today:

Back to news